Pseudophakic reliability for you and your patients
The innovative XL optic of the ASPIRA-aXA combines the advantages of a 7.0 mm optic with the stability of the new cut-out haptic design. This posterior-chamber IOL an be conveniently implanted using small-incision technology while adhering to surgical routine.
Overview of topics
MORE THAN A CONVENTIONAL IOL
The XL optic design of the posterior chamber IOL with its extended optic diameter of 7.0 mm
and permits implantation through small incisions at the same time.
THE ROUTINE REMAINS
PROVIDES THE SOLUTION
ASPIRA-aXA provides a custom solution for the most diverse needs. Possible applications range from standard cataract surgery to refractive surgery and combined interventions in retinal surgery.
FULFILLING PATIENT REQUIREMENTS
Advantages of an XL optic
With its XL optic the ASPIRA-aXA provides an ideal treatment option even under poor lighting conditions.
For an untroubled visual outcome
PREVENT PHOTIC PHENOMENA
Graphic based on a simulation using Optic Studio 16.5, Zemax with a 6 mm optic (1) and a 7 mm optic (2); pupil size – both 6 mm.
The ASPIRA-aXA with its enlarged XL optic represents a promising approach to prevent negative dysphotopsia.
Negative dysphotopsia can occur after successful cataract sugery with IOL implantation. The reasons for development of negative dysphotopsia in pseudophakic eyes seem to be multifactorial. Discussed are among others:
FOR THE DEVELOPMENT OF NEGATIVE DYSPHOTOPSIA
Numerous ray tracing analyses using standard IOLs show a non-illuminated region of the peripheral nasal retina. This “shadow” is caused by the reduced optic diameter and the central thickness of the artificial IOL compared to the natural lens.
WHAT IS THE ADVANTAGE OF AN XL OPTIC?
The panoramic IOL
From a vitreoretinal point of view, both the surgeon and the postoperative doctor benefit from the extended fundus view. The assessment of the posterior segment of the eye and the implementation of therapeutic measures for peripheral retinal diseases can occur more conveniently.
ASPIRA-aXA offers patients with an increased risk of ocular diseases an advantage for long-term, successful pseudophakic treatment.
The panoramic IOL
Outstanding material meets best-in-class technology
A MATERIAL TO WIN YOU OVER
* Zhao, H., Mainster, M. (2007). The effect of chromatic dispersion on pseudophakic optical performance. Br J Ophthalmol. 91 (9):1225-1229.
Premium IOL ASPIRA-aXA
Your advantages of the premium IOL platform
What do the experts say?
Reports from clinical application
Borkenstein A. F., Borkenstein E. M.
Creating Hybrid Monovision with 7.0 mm XL Optic and High-Add AMD Intraocular Lenses (XL-MAGS) in a Patient with Retinitis Pigmentosa
Case Rep Ophthalmol 2019;10:304-311; doi: 10.1159/000503093
Click here for full report